1. Home
  2. MIST vs RANI Comparison

MIST vs RANI Comparison

Compare MIST & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Milestone Pharmaceuticals Inc.

MIST

Milestone Pharmaceuticals Inc.

HOLD

Current Price

$0.36

Market Cap

95.3M

Sector

Health Care

ML Signal

HOLD

Logo Rani Therapeutics Holdings Inc.

RANI

Rani Therapeutics Holdings Inc.

SELL

Current Price

$0.55

Market Cap

84.6M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
MIST
RANI
Founded
2003
2012
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
95.3M
84.6M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
MIST
RANI
Price
$0.36
$0.55
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
5
Target Price
$4.14
★ $7.20
AVG Volume (30 Days)
★ 1.3M
462.4K
Earning Date
11-13-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 57.14
EPS
N/A
★ N/A
Revenue
N/A
★ $1,633,000.00
Revenue This Year
$210.30
$317.02
Revenue Next Year
$251.88
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 58.85
52 Week Low
$0.50
$0.50
52 Week High
$3.06
$1.98

Technical Indicators

Market Signals
Indicator
MIST
RANI
Relative Strength Index (RSI) 24.59 38.82
Support Level N/A $0.51
Resistance Level $0.84 $0.85
Average True Range (ATR) 0.08 0.04
MACD -0.02 0.00
Stochastic Oscillator 0.00 39.14

Price Performance

Historical Comparison
MIST
RANI

About MIST Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.

About RANI Rani Therapeutics Holdings Inc.

Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.

Share on Social Networks: